Advertisement

Virchows Archiv

, Volume 470, Issue 3, pp 245–266 | Cite as

Medication-associated gastrointestinal tract injury

  • Michael ViethEmail author
  • Elizabeth Montgomery
Invited Review

Abstract

Medication-associated gastrointestinal (GI) tract injury has been known for centuries for some medications. The more recently introduced biologicals are a class of drugs that constantly increases, and as such, the spectrum of GI tract side effects is steadily growing. This review covers not only long-known GI tract side effects of drugs but also those more recently described. A comprehensive but concise list of medications used in daily practice and associated with GI tract injury is presented.

Keywords

Gastrointestinal (GI) Biologicals Generic and trade names Medication Injury 

References

  1. 1.
    Paracelsus, von Hohenheim PAT (1574) Septem Defensiones. BaselGoogle Scholar
  2. 2.
    Douthwaite A, Lintott G (1938) Gastrosopic observation of the effect of aspirin and other substances on the stomach. The Lancet 232:1222–1224CrossRefGoogle Scholar
  3. 3.
    Parfitt JR, Driman DK (2007) Pathological effects of drugs on the gastrointestinal tract: a review. Human pathology 38:527–536. doi: 10.1016/j.humpath.2007.01.014 CrossRefPubMedGoogle Scholar
  4. 4.
    Walker NI, Bennett RE, Axelsen RA (1988) Melanosis coli. A consequence of anthraquinone-induced apoptosis of colonic epithelial cells. The American journal of pathology 131:465–476PubMedPubMedCentralGoogle Scholar
  5. 5.
    Mellouki I, Meyiz H (2013) Melanosis coli: a rarity in digestive endoscopy. The Pan African medical journal 16:86. doi: 10.11604/pamj.2013.16.86.3331 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Piccone VA, Klopstock R, LeVeen HH, Sika J (1970) Primary malignant melanoma of the esophagus associated with melanosis of the entire esophagus. First case report. The Journal of thoracic and cardiovascular surgery 59:864-870Google Scholar
  7. 7.
    Abu-Zaid A, Solimanie S, Abudan Z, Al-Hussaini H, Azzam A, Amin T (2015) Acute esophageal necrosis (black esophagus) in a 40-year-old man. Annals of Saudi medicine 35:80–81. doi: 10.5144/0256-4947.2015.80 PubMedGoogle Scholar
  8. 8.
    Gurvits GE (2013) Mortality in black esophagus. The American journal of forensic medicine and pathology 34:374. doi: 10.1097/PAF.0b013e31828ced51 CrossRefPubMedGoogle Scholar
  9. 9.
    Rigolon R, Fossa I, Rodella L, Targher G (2016) Black esophagus syndrome associated with diabetic ketoacidosis. World journal of clinical cases 4:56–59. doi: 10.12998/wjcc.v4.i2.56 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shafa S, Sharma N, Keshishian J, Dellon ES (2016) The black esophagus: a rare but deadly disease. ACG case reports journal 3:88–91CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Johnson JE, Carpenter BL, Benton J, Cross R, Eaton LA Jr, Rhoads JM (1991) Hemorrhagic colitis and pseudomelanosis coli in ipecac ingestion by proxy. Journal of pediatric gastroenterology and nutrition 12:501–506CrossRefPubMedGoogle Scholar
  12. 12.
    Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA (2010) Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Alimentary pharmacology & therapeutics 32:1124–1128. doi: 10.1111/j.1365-2036.2010.04453.x CrossRefGoogle Scholar
  13. 13.
    Yu YH, Han DS, Choi EY, Park HS, Jeong JY, Eun CS, Oh YH, Pyo JY (2012) Is use of PPIs related to increased intraepithelial lymphocytes in the colon? Digestive diseases and sciences 57:2669–2674. doi: 10.1007/s10620-012-2315-0 CrossRefPubMedGoogle Scholar
  14. 14.
    Logan RP (1996) The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection. Pharmacology & therapeutics 69:79–83CrossRefGoogle Scholar
  15. 15.
    Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH (1995) Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36:12–16CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Stolte M, Bethke B, Ruhl G, Ritter M (1992) Omeprazole-induced pseudohypertrophy of gastric parietal cells. Zeitschrift fur Gastroenterologie 30:134–138PubMedGoogle Scholar
  17. 17.
    Lundell L, Attwood S, Ell C, Fiocca R, Galmiche JP, Hatlebakk J, Lind T, Junghard O, collaborators Lt (2008) Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 57:1207–1213. doi: 10.1136/gut.2008.148833 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ (2015) Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Alimentary pharmacology & therapeutics 42:649–663. doi: 10.1111/apt.13324 CrossRefGoogle Scholar
  19. 19.
    Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M (2015) Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. The American journal of surgical pathology 39:767–771. doi: 10.1097/PAS.0000000000000385 CrossRefPubMedGoogle Scholar
  20. 20.
    Khurram M, Montgomery E (2015) Lanthanum carbonate-associated injury to the small intestine. Diagnostic Histopathology 21:452–454CrossRefGoogle Scholar
  21. 21.
    Rothenberg ME, Araya H, Longacre TA, Pasricha PJ (2015) Lanthanum-induced gastrointestinal histiocytosis. ACG case reports journal 2:187–189. doi: 10.14309/crj.2015.50 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Dumler JS, Baisden BL, Yardley JH, Raoult D (2003) Immunodetection of Tropheryma whipplei in intestinal tissues from Dr. Whipple’s 1907 patient. The New England journal of medicine 348:1411–1412. doi: 10.1056/NEJM200304033481425 CrossRefPubMedGoogle Scholar
  23. 23.
    Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C (2011) Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial AJR. American journal of roentgenology 197:W562–W570. doi: 10.2214/AJR.10.4379 CrossRefPubMedGoogle Scholar
  24. 24.
    Abraham SC, Yardley JH, Wu TT (1999) Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: an underrecognized entity. The American journal of surgical pathology. 23:1241–1247CrossRefPubMedGoogle Scholar
  25. 25.
    Banner W Jr, Tong TG (1986) Iron poisoning. Pediatric clinics of North America. 33:393–409CrossRefPubMedGoogle Scholar
  26. 26.
    Tenenbein M (2005) Unit-dose packaging of iron supplements and reduction of iron poisoning in young children. Archives of pediatrics & adolescent medicine 159:557–560. doi: 10.1001/archpedi.159.6.557 CrossRefGoogle Scholar
  27. 27.
    Eckstein RP, Symons P (1996) Iron tablets cause histopathologically distinctive lesions in mucosal biopsies of the stomach and esophagus. Pathology 28:142–145CrossRefPubMedGoogle Scholar
  28. 28.
    Vieth M, Gorgens D, Langner C (2010) Pseudoneoplastic regeneration of the stomach. Histopathology and differential diagnosis. Der Pathologe 31:171–176. doi: 10.1007/s00292-009-1266-5 CrossRefPubMedGoogle Scholar
  29. 29.
    Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. The American journal of surgical pathology 20:1161–1181CrossRefPubMedGoogle Scholar
  30. 30.
    Goldstein NS, Cinenza AN (1998) The histopathology of nonsteroidal anti-inflammatory drug-associated colitis. American journal of clinical pathology 110:622–628CrossRefPubMedGoogle Scholar
  31. 31.
    Cortina G, Wren S, Armstrong B, Lewin K, Fajardo L (1999) Clinical and pathologic overlap in nonsteroidal anti-inflammatory drug-related small bowel diaphragm disease and the neuromuscular and vascular hamartoma of the small bowel. The American journal of surgical pathology 23:1414–1417CrossRefPubMedGoogle Scholar
  32. 32.
    Joerger M (2016) Treatment regimens of classical and newer taxanes. Cancer chemotherapy and pharmacology 77:221–233. doi: 10.1007/s00280-015-2893-6 CrossRefPubMedGoogle Scholar
  33. 33.
    Daniels JA, Gibson MK, Xu L, Sun S, Canto MI, Heath E, Wang J, Brock M, Montgomery E (2008) Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. The American journal of surgical pathology 32:473–477. doi: 10.1097/PAS.0b013e3181582331 CrossRefPubMedGoogle Scholar
  34. 34.
    Hruban RH, Yardley JH, Donehower RC, Boitnott JK (1989) Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944–1950CrossRefPubMedGoogle Scholar
  35. 35.
    Iacobuzio-Donahue CA, Lee EL, Abraham SC, Yardley JH, Wu TT (2001) Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. The American journal of surgical pathology 25:1067–1073CrossRefPubMedGoogle Scholar
  36. 36.
    Jonassaint NL, Guo N, Califano JA, Montgomery EA, Armanios M (2013) The gastrointestinal manifestations of telomere-mediated disease. Aging cell 12:319–323. doi: 10.1111/acel.12041 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Torbenson M, Montgomery EA, Iacobuzio-Donahue C, Yardley JH, Wu TT, Abraham SC (2002) Colchicine effect in a colonic hyperplastic polyp. A lesion mimicking serrated adenoma. Archives of pathology & laboratory medicine 126:615–617. doi: 10.1043/0003-9985(2002)126<0615:CEIACH>2.0.CO;2 Google Scholar
  38. 38.
    Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. International journal of radiation oncology, biology, physics 68:13–23. doi: 10.1016/j.ijrobp.2006.11.060 CrossRefPubMedGoogle Scholar
  39. 39.
    Murthy R, Kamat P, Nunez R, Salem R (2008) Radioembolization of yttrium-90 microspheres for hepatic malignancy. Seminars in interventional radiology 25:48–57. doi: 10.1055/s-2008-1052306 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, Murthy R, Ryu RK, Sato KT, Miller FH, Omary RA, Salem R (2008) Biliary sequelae following radioembolization with yttrium-90 microspheres. Journal of vascular and interventional radiology : JVIR. 19:691–697. doi: 10.1016/j.jvir.2008.01.003 CrossRefPubMedGoogle Scholar
  41. 41.
    Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. Journal of vascular and interventional radiology : JVIR 18:553–561 . doi: 10.1016/j.jvir.2007.02.002quiz 562CrossRefPubMedGoogle Scholar
  42. 42.
    Medlicott SA, Ma M, Misra T, Dupre MP (2013) Vascular wall degeneration in doxycycline-related esophagitis. The American journal of surgical pathology 37:1114–1115. doi: 10.1097/PAS.0b013e31828f5a3f CrossRefPubMedGoogle Scholar
  43. 43.
    Xiao SY, Zhao L, Hart J, Semrad CE (2013) Doxycycline-induced gastric and esophageal mucosal injuries with vascular degeneration. The American journal of surgical pathology 37:1115–1116. doi: 10.1097/PAS.0b013e31828f5b3a CrossRefPubMedGoogle Scholar
  44. 44.
    Xiao SY, Zhao L, Hart J, Semrad CE (2013) Gastric mucosal necrosis with vascular degeneration induced by doxycycline. The American journal of surgical pathology 37:259–263. doi: 10.1097/PAS.0b013e31826602d8 CrossRefPubMedGoogle Scholar
  45. 45.
    Abraham SC, Bhagavan BS, Lee LA, Rashid A, Wu TT (2001) Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. The American journal of surgical pathology. 25:637–644CrossRefPubMedGoogle Scholar
  46. 46.
    Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. The American journal of medicine 126(264):e269–e224. doi: 10.1016/j.amjmed.2012.08.016 Google Scholar
  47. 47.
    Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM (1987) Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery 101:267–272PubMedGoogle Scholar
  48. 48.
    Rashid A, Hamilton SR (1997) Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. The American journal of surgical pathology 21:60–69CrossRefPubMedGoogle Scholar
  49. 49.
    Voltaggio L, Lam-Himlin D, Limketkai BN, Singhi AD, Arnold CA (2014) Message in a bottle: decoding medication injury patterns in the gastrointestinal tract. Journal of clinical pathology 67:903–912. doi: 10.1136/jclinpath-2014-202511 CrossRefPubMedGoogle Scholar
  50. 50.
    Arnold MA, Swanson BJ, Crowder CD, Frankel WL, Lam-Himlin D, Singhi AD, Stanich PP, Arnold CA (2014) Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. The American journal of surgical pathology. 38:1530–1537. doi: 10.1097/PAS.0000000000000260 CrossRefPubMedGoogle Scholar
  51. 51.
    Swanson BJ, Limketkai BN, Liu TC, Montgomery E, Nazari K, Park JY, Santangelo WC, Torbenson MS, Voltaggio L, Yearsley MM, Arnold CA (2013) Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. The American journal of surgical pathology 37:1686–1693. doi: 10.1097/PAS.0b013e3182999d8d CrossRefPubMedGoogle Scholar
  52. 52.
    Boonyawat K, Wongwaisayawan S, Nitiyanant P, Atichartakarn V (2014) Hydroxyurea and colonic ulcers: a case report BMC gastroenterology 14:134. doi:  10.1186/1471-230X-14-134
  53. 53.
    Antar A, Ishak RS, Otrock ZK, El-Majzoub N, Ghosn S, Mahfouz R, Taher AT (2014) Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. Hematology/oncology and stem cell therapy. 7:166–169. doi: 10.1016/j.hemonc.2014.09.008 CrossRefPubMedGoogle Scholar
  54. 54.
    Martin MC, Cristiano E, Villanueva M, Bonora ML, Berguio N, Tocci A, Groisman B, Bidondo MP, Liascovich R, Barbero P (2014) Esophageal atresia and prenatal exposure to mycophenolate. Reproductive toxicology 50:117–121. doi: 10.1016/j.reprotox.2014.10.015 CrossRefPubMedGoogle Scholar
  55. 55.
    Zaheer F, Berger JR (2012) Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Therapeutic advances in drug safety 3:227–239. doi: 10.1177/2042098612453849 CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A, Ramos E, Klassen DK, Drachenberg CB (2003) Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. International journal of surgical pathology 11:295–302CrossRefPubMedGoogle Scholar
  57. 57.
    Papadimitriou JC, Drachenberg CB, Beskow CO, Cangro C, Wiland A, Klassen D, Weir M, Bartlett S (2001) Graft-versus-host disease-like features in mycophenolate mofetil-related colitis. Transplantation proceedings 33:2237–2238CrossRefPubMedGoogle Scholar
  58. 58.
    Nguyen T, Park JY, Scudiere JR, Montgomery E (2009) Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract. The American journal of surgical pathology 33:1355–1363. doi: 10.1097/PAS.0b013e3181a755bd CrossRefPubMedGoogle Scholar
  59. 59.
    Star KV, Ho VT, Wang HH, Odze RD (2013) Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. The American journal of surgical pathology 37:1319–1328. doi: 10.1097/PAS.0b013e31829ab1ef CrossRefPubMedGoogle Scholar
  60. 60.
    Freeman HJ (2012) Colitis associated with biological agents. World journal of gastroenterology 18:1871–1874. doi: 10.3748/wjg.v18.i16.1871 CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 363:711–723. doi: 10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Khoja L, Atenafu EG, Ye Q, Gedye C, Chappell M, Hogg D, Butler MO, Joshua AM (2016) Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology letters 11:1581–1585. doi: 10.3892/ol.2015.4069 PubMedGoogle Scholar
  63. 63.
    Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY (2008) Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. The American journal of surgical pathology 32:1130–1137. doi: 10.1097/PAS.0b013e31817150e3 CrossRefPubMedGoogle Scholar
  64. 64.
    Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA (2015) Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. The American journal of surgical pathology 39:1075–1084. doi: 10.1097/PAS.0000000000000453 CrossRefPubMedGoogle Scholar
  65. 65.
    Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine 372:2018–2028. doi: 10.1056/NEJMoa1501824 CrossRefPubMedGoogle Scholar
  66. 66.
    Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA (2016) PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. The New England journal of medicine 374:2542–2552. doi: 10.1056/NEJMoa1603702 CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015) Pembrolizumab versus ipilimumab in advanced melanoma. The New England journal of medicine 372:2521–2532. doi: 10.1056/NEJMoa1503093 CrossRefPubMedGoogle Scholar
  68. 68.
    Wilkinson E (2015) Nivolumab success in untreated metastatic melanoma. The Lancet. Oncology 16:e9. doi: 10.1016/S1470-2045(14)71129-5 CrossRefPubMedGoogle Scholar
  69. 69.
    Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine 369:122–133. doi: 10.1056/NEJMoa1302369 CrossRefPubMedGoogle Scholar
  70. 70.
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. The New England journal of medicine 372:2509–2520. doi: 10.1056/NEJMoa1500596 CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology 16:908–918. doi: 10.1016/S1470-2045(15)00083-2 CrossRefPubMedGoogle Scholar
  72. 72.
    Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ (2016) Fulminant myocarditis with combination immune checkpoint blockade. The New England journal of medicine 375:1749–1755. doi: 10.1056/NEJMoa1609214 CrossRefPubMedGoogle Scholar
  73. 73.
    Postow MA (2015) Managing immune checkpoint-blocking antibody side effects American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting:76-83. doi:  10.14694/EdBook_AM.2015.35.76
  74. 74.
    Green MC, Murray JL, Hortobagyi GN (2000) Monoclonal antibody therapy for solid tumors. Cancer treatment reviews 26:269–286. doi: 10.1053/ctrv.2000.0176 CrossRefPubMedGoogle Scholar
  75. 75.
    Blombery P, Prince HM, Levinson M, Pianko S, Maxwell E, Bhathal P (2011) Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29:e110–e112. doi: 10.1200/JCO.2010.31.8899 CrossRefGoogle Scholar
  76. 76.
    Lipka S, Katz S, Crawford JM (2016) Fulminant colitis following rituximab. Therapy Gastroenterology & hepatology 12:58–60Google Scholar
  77. 77.
    Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H (2013) Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. The American journal of surgical pathology 37:563–570. doi: 10.1097/PAS.0b013e3182759008 CrossRefPubMedGoogle Scholar
  78. 78.
    Barrientos JC (2016) Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. OncoTargets and therapy 9:2945–2953. doi: 10.2147/OTT.S102573 CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. The American journal of surgical pathology 39:1653–1660. doi: 10.1097/PAS.0000000000000525 CrossRefPubMedGoogle Scholar
  80. 80.
    Weidner AS, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, Jessurun J, Yantiss RK (2015) Idelalisib-associated colitis: histologic findings in 14 patients. The American journal of surgical pathology 39:1661–1667. doi: 10.1097/PAS.0000000000000522 CrossRefPubMedGoogle Scholar
  81. 81.
    Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England journal of medicine 372:621–630. doi: 10.1056/NEJMoa1406470 CrossRefPubMedGoogle Scholar
  82. 82.
    Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clinic proceedings 87:732–738. doi: 10.1016/j.mayocp.2012.06.003 CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S (2016) Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human pathology 50:127–134. doi: 10.1016/j.humpath.2015.12.001 CrossRefPubMedGoogle Scholar
  84. 84.
    Lagana SM, Braunstein ED, Arguelles-Grande C, Bhagat G, Green PH, Lebwohl B (2015) Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. Journal of clinical pathology 68:29–32. doi: 10.1136/jclinpath-2014-202615 CrossRefPubMedGoogle Scholar
  85. 85.
    Choi EY, McKenna BJ (2015) Olmesartan-associated enteropathy: a review of clinical and Histologic findings Archives of pathology & laboratory medicine 139:1242-1247. doi:  10.5858/arpa.2015-0204-RA
  86. 86.
    Marietta EV, Nadeau AM, Cartee AK, Singh I, Rishi A, Choung RS, Wu TT, Rubio-Tapia A, Murray JA (2015) Immunopathogenesis of olmesartan-associated enteropathy. Alimentary pharmacology & therapeutics 42:1303–1314. doi: 10.1111/apt.13413 CrossRefGoogle Scholar
  87. 87.
    Jevremovic D, Torbenson M, Murray JA, Burgart LJ, Abraham SC (2006) Atrophic autoimmune pangastritis: a distinctive form of antral and fundic gastritis associated with systemic autoimmune disease. The American journal of surgical pathology 30:1412–1419. doi: 10.1097/01.pas.0000213337.25111.37 CrossRefPubMedGoogle Scholar
  88. 88.
    Akram S, Murray JA, Pardi DS, Alexander GL, Schaffner JA, Russo PA, Abraham SC (2007) Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 5:1282–1290 . doi: 10.1016/j.cgh.2007.05.013quiz 1245CrossRefGoogle Scholar
  89. 89.
    Daniels JA, Lederman HM, Maitra A, Montgomery EA (2007) Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. The American journal of surgical pathology 31:1800–1812. doi: 10.1097/PAS.0b013e3180cab60c CrossRefPubMedGoogle Scholar
  90. 90.
    Greenson JK (2015) The biopsy pathology of non-coeliac enteropathy. Histopathology 66:29–36. doi: 10.1111/his.12522 CrossRefPubMedGoogle Scholar
  91. 91.
    Stanich PP, Yearsley M, Meyer MM (2013) Olmesartan-associated sprue-like enteropathy. Journal of clinical gastroenterology 47:894–895. doi: 10.1097/MCG.0b013e31829a27e6 CrossRefPubMedGoogle Scholar
  92. 92.
    Dejaco C, Oesterreicher C, Angelberger S, Puspok A, Birner P, Poetzi R, Gangl A, Oberhuber G (2003) Diagnosing colitis: a prospective study on essential parameters for reaching a diagnosis. Endoscopy 35:1004–1008. doi: 10.1055/s-2003-44593 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Institute for PathologyKlinikum BayreuthBayreuthGermany
  2. 2.Johns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations